ReP USP - Resultado da busca

Artigo de periodico
Serum levels of VEGF and MCSF in HER2+/HER2- breast cancer patients with metronomic neoadjuvant chemotherapy (2018)
Arai, Roberto J.; Hoff, Paulo M.; Mano, Max S.; Petry, Vanessa
Source: Biomarker research. Unidade: FM
Subjects: QUIMIOTERAPIA ADJUVANTE, CÉLULAS ENDOTELIAIS, CO-TERAPIA, NEOPLASIAS MAMÁRIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ARAI, Roberto J. et al. Serum levels of VEGF and MCSF in HER2+/HER2- breast cancer patients with metronomic neoadjuvant chemotherapy. Biomarker research, v. 6, 2018Tradução . . Disponível em: https://doi.org/10.1186/s40364-018-0135-x. Acesso em: 18 nov. 2024.
APA
Arai, R. J., Hoff, P. M., Mano, M. S., & Petry, V. (2018). Serum levels of VEGF and MCSF in HER2+/HER2- breast cancer patients with metronomic neoadjuvant chemotherapy. Biomarker research, 6. doi:10.1186/s40364-018-0135-x
NLM
Arai RJ, Hoff PM, Mano MS, Petry V. Serum levels of VEGF and MCSF in HER2+/HER2- breast cancer patients with metronomic neoadjuvant chemotherapy [Internet]. Biomarker research. 2018 ; 6[citado 2024 nov. 18 ] Available from: https://doi.org/10.1186/s40364-018-0135-x
Vancouver
Arai RJ, Hoff PM, Mano MS, Petry V. Serum levels of VEGF and MCSF in HER2+/HER2- breast cancer patients with metronomic neoadjuvant chemotherapy [Internet]. Biomarker research. 2018 ; 6[citado 2024 nov. 18 ] Available from: https://doi.org/10.1186/s40364-018-0135-x
Artigo de periodico
The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia (2018)
Overman, Michael J.; Hoff, Paulo M.
Source: Jnci-journal of the national cancer institute. Unidade: FM
Subjects: ANTINEOPLÁSICOS, METÁSTASE NEOPLÁSICA, NEOPLASIAS COLORRETAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OVERMAN, Michael J. e HOFF, Paulo M. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. Jnci-journal of the national cancer institute, v. 110, n. 8, p. 888-894, 2018Tradução . . Disponível em: https://doi.org/10.1093/jnci/djx288. Acesso em: 18 nov. 2024.
APA
Overman, M. J., & Hoff, P. M. (2018). The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. Jnci-journal of the national cancer institute, 110( 8), 888-894. doi:10.1093/jnci/djx288
NLM
Overman MJ, Hoff PM. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia [Internet]. Jnci-journal of the national cancer institute. 2018 ; 110( 8): 888-894.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1093/jnci/djx288
Vancouver
Overman MJ, Hoff PM. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia [Internet]. Jnci-journal of the national cancer institute. 2018 ; 110( 8): 888-894.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1093/jnci/djx288
Artigo de periodico
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project (2018)
Sjoquist, Katrin M.; Hoff, Paulo M.
Source: Jnci-journal of the national cancer institute. Unidade: FM
Subjects: NEOPLASIAS COLORRETAIS, BIOMARCADORES, MÉDICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SJOQUIST, Katrin M. e HOFF, Paulo M. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. Jnci-journal of the national cancer institute, v. 110, n. 6, p. 638-648, 2018Tradução . . Disponível em: https://doi.org/10.1093/jnci/djx253. Acesso em: 18 nov. 2024.
APA
Sjoquist, K. M., & Hoff, P. M. (2018). Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. Jnci-journal of the national cancer institute, 110( 6), 638-648. doi:10.1093/jnci/djx253
NLM
Sjoquist KM, Hoff PM. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project [Internet]. Jnci-journal of the national cancer institute. 2018 ; 110( 6): 638-648.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1093/jnci/djx253
Vancouver
Sjoquist KM, Hoff PM. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project [Internet]. Jnci-journal of the national cancer institute. 2018 ; 110( 6): 638-648.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1093/jnci/djx253
Artigo de periodico
Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care? (2017)
Fernandes, Gustavo S.; Marques, Daniel F.; Girardi, Daniel M.; Braghiroli, Maria Ignez F.; Coudry, Renata A.; Meireles, Sibele I.; Katz, Artur; Hoff, Paulo M.
Source: Clinics. Unidade: FM
Subjects: NEOPLASIAS, GENÔMICA, ANÁLISE DE SEQUÊNCIA DE DNA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERNANDES, Gustavo S. et al. Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?. Clinics, v. 72, n. 10, p. 588-594, 2017Tradução . . Disponível em: https://doi.org/10.6061/clinics/2017(10)01. Acesso em: 18 nov. 2024.
APA
Fernandes, G. S., Marques, D. F., Girardi, D. M., Braghiroli, M. I. F., Coudry, R. A., Meireles, S. I., et al. (2017). Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care? Clinics, 72( 10), 588-594. doi:10.6061/clinics/2017(10)01
NLM
Fernandes GS, Marques DF, Girardi DM, Braghiroli MIF, Coudry RA, Meireles SI, Katz A, Hoff PM. Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care? [Internet]. Clinics. 2017 ; 72( 10): 588-594.[citado 2024 nov. 18 ] Available from: https://doi.org/10.6061/clinics/2017(10)01
Vancouver
Fernandes GS, Marques DF, Girardi DM, Braghiroli MIF, Coudry RA, Meireles SI, Katz A, Hoff PM. Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care? [Internet]. Clinics. 2017 ; 72( 10): 588-594.[citado 2024 nov. 18 ] Available from: https://doi.org/10.6061/clinics/2017(10)01
Artigo de periodico
Pathology of Anal Cancer (2017)
Hoff, Paulo M.; Coudry, Renata; Moniz, Camila Motta Venchiarutti
Source: Surgical Oncology Clinics of North America. Unidade: FM
Subjects: HPV, BIOMARCADORES, CARCINOMA DE CÉLULAS ESCAMOSAS, NEOPLASIAS COLORRETAIS, ANUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HOFF, Paulo M. e COUDRY, Renata e MONIZ, Camila Motta Venchiarutti. Pathology of Anal Cancer. Surgical Oncology Clinics of North America, v. 26, n. 1, p. 57-71, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.soc.2016.07.013. Acesso em: 18 nov. 2024.
APA
Hoff, P. M., Coudry, R., & Moniz, C. M. V. (2017). Pathology of Anal Cancer. Surgical Oncology Clinics of North America, 26( 1), 57-71. doi:10.1016/j.soc.2016.07.013
NLM
Hoff PM, Coudry R, Moniz CMV. Pathology of Anal Cancer [Internet]. Surgical Oncology Clinics of North America. 2017 ; 26( 1): 57-71.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.soc.2016.07.013
Vancouver
Hoff PM, Coudry R, Moniz CMV. Pathology of Anal Cancer [Internet]. Surgical Oncology Clinics of North America. 2017 ; 26( 1): 57-71.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.soc.2016.07.013
Artigo de periodico
The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment (2017)
Connell, Louise C.; Mota, Jose Mauricio; Braghiroli, Maria Ignez; Hoff, Paulo M.
Source: Current treatment options in oncology. Unidade: FM
Subjects: FATORES ETÁRIOS, ESTUDOS DE COORTES, EPIDEMIOLOGIA ANALÍTICA, ADOLESCENTES, NEOPLASIAS COLORRETAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CONNELL, Louise C. et al. The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment. Current treatment options in oncology, v. 18, n. 23, p. 1-20, 2017Tradução . . Disponível em: https://doi.org/10.1007%2Fs11864-017-0463-3. Acesso em: 18 nov. 2024.
APA
Connell, L. C., Mota, J. M., Braghiroli, M. I., & Hoff, P. M. (2017). The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment. Current treatment options in oncology, 18( 23), 1-20. doi:10.1007%2Fs11864-017-0463-3
NLM
Connell LC, Mota JM, Braghiroli MI, Hoff PM. The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment [Internet]. Current treatment options in oncology. 2017 ; 18( 23): 1-20.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007%2Fs11864-017-0463-3
Vancouver
Connell LC, Mota JM, Braghiroli MI, Hoff PM. The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment [Internet]. Current treatment options in oncology. 2017 ; 18( 23): 1-20.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007%2Fs11864-017-0463-3
Artigo de periodico
Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community (2017)
Protásio, Bruno Mendonça; Matutino, Adriana; Lage, Liana Valente; Santana, Iuri; Ramos, Ricardo; Sabbaga, Jorge; Capareli, Fernanda; Saragiotto, Daniel; Riechelmann, Rachel P.; Hoff, Paulo M.
Source: Clinical Colorectal Cancer. Unidade: FM
Subjects: NEOPLASIAS COLORRETAIS, QUIMIOTERAPIA ADJUVANTE, ANTINEOPLÁSICOS, AVANÇO DA DOENÇA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PROTÁSIO, Bruno Mendonça et al. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community. Clinical Colorectal Cancer, v. 16, n. 1, p. 65-72, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.clcc.2016.07.001. Acesso em: 18 nov. 2024.
APA
Protásio, B. M., Matutino, A., Lage, L. V., Santana, I., Ramos, R., Sabbaga, J., et al. (2017). Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community. Clinical Colorectal Cancer, 16( 1), 65-72. doi:10.1016/j.clcc.2016.07.001
NLM
Protásio BM, Matutino A, Lage LV, Santana I, Ramos R, Sabbaga J, Capareli F, Saragiotto D, Riechelmann RP, Hoff PM. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community [Internet]. Clinical Colorectal Cancer. 2017 ; 16( 1): 65-72.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.clcc.2016.07.001
Vancouver
Protásio BM, Matutino A, Lage LV, Santana I, Ramos R, Sabbaga J, Capareli F, Saragiotto D, Riechelmann RP, Hoff PM. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community [Internet]. Clinical Colorectal Cancer. 2017 ; 16( 1): 65-72.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.clcc.2016.07.001
Artigo de periodico
Diretrizes para o tratamento de tumores neuroendócrinos pelo grupo brasileiro de pesquisa em tumor gastrointestinal (2017)
Rachel P Riechelmann,; Weschenfelder, Rui F.; Costa, Frederico P.; Andrade, Aline Chaves; Osvaldt, Alessandro Bersch; Quidute, Ana Rosa P.; Santos, Allan dos; Hoff, Ana Amélia O.; Gumz, Brenda; Buchpiguel, Carlos; Pereira, Bruno S. Vilhena; Lourenço Junior, Delmar Muniz; Rocha Filho, Duilio Reis da; Fonseca, Eduardo Antunes; Mello, Eduardo Linhares Riello; Makdissi, Fabio Ferrari; Waechter, Fabio Luiz; Carnevale, Francisco Cesar; Coura-Filho, George B.; Paulo, Gustavo Andrade de; Girotto, Gustavo Colagiovanni; Bezerra Neto, João Evangelista; Glasberg, João; Casali-da-Rocha, Jose Claudio; Rego, Juliana Florinda M.; Meirelles, Luciana Rodrigues de; Hajjar, Ludhmila; Menezes, Marcos; Bronstein, Marcello D.; Sapienza, Marcelo Tatit; Fragoso, Maria Candida Barisson Villares; Pereira, Maria Adelaide Albergaria; Barras, Milton; Forones, Nora Manoukian; Amaral, Paulo Cezar Galvão do; Medeiros, Raphael Salles Scortegagna de; Araujo, Raphael L. C.; Bezerra, Regis Otaviano França; Peixoto, Renata D’Alpino; Aguiar Jr., Samuel; Ribeiro Jr., Ulysses; Pfiffer, Tulio; Hoff, Paulo M.; Coutinho, Anelisa K.
Source: ecancermedicalscience. Unidade: FM
Subjects: NEOPLASIAS POR LOCALIZAÇÃO, DIRETRIZES PARA A PRÁTICA CLÍNICA, NEUROENDOCRINOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RACHEL P RIECHELMANN, et al. Diretrizes para o tratamento de tumores neuroendócrinos pelo grupo brasileiro de pesquisa em tumor gastrointestinal. ecancermedicalscience, v. 11, 2017Tradução . . Disponível em: https://doi.org/10.3332/ecancer.2017.716. Acesso em: 18 nov. 2024.
APA
Rachel P Riechelmann,, Weschenfelder, R. F., Costa, F. P., Andrade, A. C., Osvaldt, A. B., Quidute, A. R. P., et al. (2017). Diretrizes para o tratamento de tumores neuroendócrinos pelo grupo brasileiro de pesquisa em tumor gastrointestinal. ecancermedicalscience, 11. doi:10.3332/ecancer.2017.716
NLM
Rachel P Riechelmann, Weschenfelder RF, Costa FP, Andrade AC, Osvaldt AB, Quidute ARP, Santos A dos, Hoff AAO, Gumz B, Buchpiguel C, Pereira BSV, Lourenço Junior DM, Rocha Filho DR da, Fonseca EA, Mello ELR, Makdissi FF, Waechter FL, Carnevale FC, Coura-Filho GB, Paulo GA de, Girotto GC, Bezerra Neto JE, Glasberg J, Casali-da-Rocha JC, Rego JFM, Meirelles LR de, Hajjar L, Menezes M, Bronstein MD, Sapienza MT, Fragoso MCBV, Pereira MAA, Barras M, Forones NM, Amaral PCG do, Medeiros RSS de, Araujo RLC, Bezerra ROF, Peixoto RD’A, Aguiar Jr. S, Ribeiro Jr. U, Pfiffer T, Hoff PM, Coutinho AK. Diretrizes para o tratamento de tumores neuroendócrinos pelo grupo brasileiro de pesquisa em tumor gastrointestinal [Internet]. ecancermedicalscience. 2017 ; 11[citado 2024 nov. 18 ] Available from: https://doi.org/10.3332/ecancer.2017.716
Vancouver
Rachel P Riechelmann, Weschenfelder RF, Costa FP, Andrade AC, Osvaldt AB, Quidute ARP, Santos A dos, Hoff AAO, Gumz B, Buchpiguel C, Pereira BSV, Lourenço Junior DM, Rocha Filho DR da, Fonseca EA, Mello ELR, Makdissi FF, Waechter FL, Carnevale FC, Coura-Filho GB, Paulo GA de, Girotto GC, Bezerra Neto JE, Glasberg J, Casali-da-Rocha JC, Rego JFM, Meirelles LR de, Hajjar L, Menezes M, Bronstein MD, Sapienza MT, Fragoso MCBV, Pereira MAA, Barras M, Forones NM, Amaral PCG do, Medeiros RSS de, Araujo RLC, Bezerra ROF, Peixoto RD’A, Aguiar Jr. S, Ribeiro Jr. U, Pfiffer T, Hoff PM, Coutinho AK. Diretrizes para o tratamento de tumores neuroendócrinos pelo grupo brasileiro de pesquisa em tumor gastrointestinal [Internet]. ecancermedicalscience. 2017 ; 11[citado 2024 nov. 18 ] Available from: https://doi.org/10.3332/ecancer.2017.716
Artigo de periodico
Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting (2016)
Santana, Iuri A.; Oliveira, Julia Andrade; Lima, Julianne Maria da Silva; Testa, Laura; Piato, José Roberto M.; Hoff, Paulo M.; Mano, Max S.
Source: Breast cancer. Unidade: FM
Subjects: NEOPLASIAS MAMÁRIAS, ANTINEOPLÁSICOS, EVENTO ADVERSO A MEDICAMENTO, BRASIL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTANA, Iuri A. et al. Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting. Breast cancer, v. 23, n. 2, p. 261-265, 2016Tradução . . Disponível em: http://link.springer.com/article/10.1007%2Fs12282-014-0564-9. Acesso em: 18 nov. 2024.
APA
Santana, I. A., Oliveira, J. A., Lima, J. M. da S., Testa, L., Piato, J. R. M., Hoff, P. M., & Mano, M. S. (2016). Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting. Breast cancer, 23( 2), 261-265. doi:10.1007/s12282-014-0564-9
NLM
Santana IA, Oliveira JA, Lima JM da S, Testa L, Piato JRM, Hoff PM, Mano MS. Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting [Internet]. Breast cancer. 2016 ; 23( 2): 261-265.[citado 2024 nov. 18 ] Available from: http://link.springer.com/article/10.1007%2Fs12282-014-0564-9
Vancouver
Santana IA, Oliveira JA, Lima JM da S, Testa L, Piato JRM, Hoff PM, Mano MS. Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting [Internet]. Breast cancer. 2016 ; 23( 2): 261-265.[citado 2024 nov. 18 ] Available from: http://link.springer.com/article/10.1007%2Fs12282-014-0564-9
Artigo de periodico
Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database (2015)
Shi, Qian; Gramont, Aimery de; Grothey, Axel; Zalcberg, John; Chibaudel, Benoist; Schmoll, Hans-Joachim; Seymour, Matthew T.; Adams, Richard; Saltz, Leonard; Goldberg, Richard M.; Punt, Cornelis J. A.; Douillard, Jean-Yves; Hoff, Paulo M.; Hecht, Joel Randolph; Hurwitz, Herbert; Díaz-Rubio, Eduardo; Porschen, Rainer; Tebbutt, Niall C.; Fuchs, Charles; Souglakos, John; Falcone, Alfredo; Tournigand, Christophe; Kabbinavar, Fairooz F.; Heinemann, Volker; Cutsem, Eric Van; Bokemeyer, Carsten; Buyse, Marc; Sargent, Daniel J.
Source: Journal of Clinical Oncology. Unidade: FM
Subjects: NEOPLASIAS COLORRETAIS, PROGNÓSTICO, METÁSTASE NEOPLÁSICA, ESTUDOS RANDOMIZADOS, NEOPLASIAS DO SISTEMA DIGESTÓRIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SHI, Qian et al. Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. Journal of Clinical Oncology, v. 33, n. 1, p. 22-28, 2015Tradução . . Disponível em: https://doi.org/10.1200/JCO.2014.56.5887. Acesso em: 18 nov. 2024.
APA
Shi, Q., Gramont, A. de, Grothey, A., Zalcberg, J., Chibaudel, B., Schmoll, H. -J., et al. (2015). Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. Journal of Clinical Oncology, 33( 1), 22-28. doi:10.1200/JCO.2014.56.5887
NLM
Shi Q, Gramont A de, Grothey A, Zalcberg J, Chibaudel B, Schmoll H-J, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJA, Douillard J-Y, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Cutsem EV, Bokemeyer C, Buyse M, Sargent DJ. Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database [Internet]. Journal of Clinical Oncology. 2015 ; 33( 1): 22-28.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1200/JCO.2014.56.5887
Vancouver
Shi Q, Gramont A de, Grothey A, Zalcberg J, Chibaudel B, Schmoll H-J, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJA, Douillard J-Y, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Cutsem EV, Bokemeyer C, Buyse M, Sargent DJ. Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database [Internet]. Journal of Clinical Oncology. 2015 ; 33( 1): 22-28.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1200/JCO.2014.56.5887
Artigo de periodico
The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4 (2015)
Teixeira, Marcela Crosara; Marques, Daniel Fernandes; Ferrari, Anezka Celis; Alves, Michel Fabiano Silva; Alex, Alexandra Khichfy; Sabbaga, Jorge; Hoff, Paulo M.; Riechelmann, Rachel P.
Source: Clinical Colorectal Cancer. Unidade: FM
Subjects: NEOPLASIAS COLORRETAIS (QUIMIOTERAPIA), METÁSTASE NEOPLÁSICA, CUIDADOS PALIATIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TEIXEIRA, Marcela Crosara et al. The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4. Clinical Colorectal Cancer, v. 14, n. 1, p. 52-57, 2015Tradução . . Disponível em: https://doi.org/10.1016/j.clcc.2014.09.010. Acesso em: 18 nov. 2024.
APA
Teixeira, M. C., Marques, D. F., Ferrari, A. C., Alves, M. F. S., Alex, A. K., Sabbaga, J., et al. (2015). The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4. Clinical Colorectal Cancer, 14( 1), 52-57. doi:10.1016/j.clcc.2014.09.010
NLM
Teixeira MC, Marques DF, Ferrari AC, Alves MFS, Alex AK, Sabbaga J, Hoff PM, Riechelmann RP. The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4 [Internet]. Clinical Colorectal Cancer. 2015 ; 14( 1): 52-57.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.clcc.2014.09.010
Vancouver
Teixeira MC, Marques DF, Ferrari AC, Alves MFS, Alex AK, Sabbaga J, Hoff PM, Riechelmann RP. The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4 [Internet]. Clinical Colorectal Cancer. 2015 ; 14( 1): 52-57.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.clcc.2014.09.010
Artigo de periodico
Adherence to colonoscopy recommendations for first-degree relatives of young patients diagnosed with colorectal cancer (2015)
Garcia, Guilherme H.; Riechelmann, Rachel P.; Hoff, Paulo M.
Source: Clinics. Unidade: FM
Subjects: FATORES DE RISCO, COLONOSCOPIA, DOENÇAS HEREDITÁRIAS, NEOPLASIAS COLORRETAIS (PREVENÇÃO E CONTROLE)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GARCIA, Guilherme H. e RIECHELMANN, Rachel P. e HOFF, Paulo M. Adherence to colonoscopy recommendations for first-degree relatives of young patients diagnosed with colorectal cancer. Clinics, v. 70, n. 10, p. 696-699, 2015Tradução . . Disponível em: https://doi.org/10.6061/clinics/2015(10)07. Acesso em: 18 nov. 2024.
APA
Garcia, G. H., Riechelmann, R. P., & Hoff, P. M. (2015). Adherence to colonoscopy recommendations for first-degree relatives of young patients diagnosed with colorectal cancer. Clinics, 70( 10), 696-699. doi:10.6061/clinics/2015(10)07
NLM
Garcia GH, Riechelmann RP, Hoff PM. Adherence to colonoscopy recommendations for first-degree relatives of young patients diagnosed with colorectal cancer [Internet]. Clinics. 2015 ; 70( 10): 696-699.[citado 2024 nov. 18 ] Available from: https://doi.org/10.6061/clinics/2015(10)07
Vancouver
Garcia GH, Riechelmann RP, Hoff PM. Adherence to colonoscopy recommendations for first-degree relatives of young patients diagnosed with colorectal cancer [Internet]. Clinics. 2015 ; 70( 10): 696-699.[citado 2024 nov. 18 ] Available from: https://doi.org/10.6061/clinics/2015(10)07
Parte de monografia/livro
Obesidade e câncer (2015)
Atta, José Antonio; Hoff, Paulo M.
Source: Tratado de obesidade : 2. ed. Unidade: FM
Subjects: OBESIDADE, INSULINA, ESTRÓGENOS, NEOPLASIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ATTA, José Antonio e HOFF, Paulo M. Obesidade e câncer. Tratado de obesidade : 2. ed. Tradução . Rio de Janeiro: Guanabara Koogan, 2015. . . Acesso em: 18 nov. 2024.
APA
Atta, J. A., & Hoff, P. M. (2015). Obesidade e câncer. In Tratado de obesidade : 2. ed. Rio de Janeiro: Guanabara Koogan.
NLM
Atta JA, Hoff PM. Obesidade e câncer. In: Tratado de obesidade : 2. ed. Rio de Janeiro: Guanabara Koogan; 2015. [citado 2024 nov. 18 ]
Vancouver
Atta JA, Hoff PM. Obesidade e câncer. In: Tratado de obesidade : 2. ed. Rio de Janeiro: Guanabara Koogan; 2015. [citado 2024 nov. 18 ]
Artigo de periodico
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy (2015)
Ruff, Paul; Ferry, David R.; Lakomỳ, Radek; McWalter, Gael; Van Hazel, Guy A.; Hoff, Paulo M.; Cunningham, David; Arnold, Dirk; Schmoll, Hans J.; Moiseyenko, Vladimir M.; McKendrick, Joseph J.; ten Tije, Albert J.; Vishwanath, Raghu L.; Bhargava, Pankaj; Chevalier, Soazig; Macarulla, Teresa; Cutsem, Eric Van
Source: European Journal of Cancer. Unidade: FM
Subjects: NEOPLASIAS COLORRETAIS (TERAPIA), FATORES DE CRESCIMENTO, QUIMIOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RUFF, Paul et al. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. European Journal of Cancer, v. 51, n. 1, p. 18-26, 2015Tradução . . Disponível em: https://doi.org/10.1016/j.ejca.2014.10.019. Acesso em: 18 nov. 2024.
APA
Ruff, P., Ferry, D. R., Lakomỳ, R., McWalter, G., Van Hazel, G. A., Hoff, P. M., et al. (2015). Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. European Journal of Cancer, 51( 1), 18-26. doi:10.1016/j.ejca.2014.10.019
NLM
Ruff P, Ferry DR, Lakomỳ R, McWalter G, Van Hazel GA, Hoff PM, Cunningham D, Arnold D, Schmoll HJ, Moiseyenko VM, McKendrick JJ, ten Tije AJ, Vishwanath RL, Bhargava P, Chevalier S, Macarulla T, Cutsem EV. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy [Internet]. European Journal of Cancer. 2015 ; 51( 1): 18-26.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.ejca.2014.10.019
Vancouver
Ruff P, Ferry DR, Lakomỳ R, McWalter G, Van Hazel GA, Hoff PM, Cunningham D, Arnold D, Schmoll HJ, Moiseyenko VM, McKendrick JJ, ten Tije AJ, Vishwanath RL, Bhargava P, Chevalier S, Macarulla T, Cutsem EV. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy [Internet]. European Journal of Cancer. 2015 ; 51( 1): 18-26.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.ejca.2014.10.019
Artigo de periodico
Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial (2014)
Hoff, Paulo M.; Saragiotto, Daniel F.; Barrios, Carlos H.; Giglio, Auro del; Coutinho, Anelisa K.; Andrade, Aline C.; Dutra, Carolina; Forones, Nora M.; Correa, Mariangela; Portella, Maria do Socorro O.; Passos, Vanessa Q.; Chinen, Renata N.; Eyll, Brigitte van
Source: Journal of Clinical Oncology. Unidade: FM
Subjects: QUIMIOTERAPIA, NEOPLASIAS COLORRETAIS (COMPLICAÇÕES), DIARREIA (TERAPIA), ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HOFF, Paulo M. et al. Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial. Journal of Clinical Oncology, v. 32, n. 10, p. 1006-1011, 2014Tradução . . Disponível em: https://doi.org/10.1200/JCO.2013.50.8077. Acesso em: 18 nov. 2024.
APA
Hoff, P. M., Saragiotto, D. F., Barrios, C. H., Giglio, A. del, Coutinho, A. K., Andrade, A. C., et al. (2014). Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial. Journal of Clinical Oncology, 32( 10), 1006-1011. doi:10.1200/JCO.2013.50.8077
NLM
Hoff PM, Saragiotto DF, Barrios CH, Giglio A del, Coutinho AK, Andrade AC, Dutra C, Forones NM, Correa M, Portella M do SO, Passos VQ, Chinen RN, Eyll B van. Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial [Internet]. Journal of Clinical Oncology. 2014 ; 32( 10): 1006-1011.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1200/JCO.2013.50.8077
Vancouver
Hoff PM, Saragiotto DF, Barrios CH, Giglio A del, Coutinho AK, Andrade AC, Dutra C, Forones NM, Correa M, Portella M do SO, Passos VQ, Chinen RN, Eyll B van. Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial [Internet]. Journal of Clinical Oncology. 2014 ; 32( 10): 1006-1011.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1200/JCO.2013.50.8077
Artigo de periodico
Is surgery always necessary in rectal cancer? (2014)
Sabbaga, Jorge; Braghiroli, Maria Ignez; Hoff, Paulo M.
Source: Oncology. Unidade: FM
Subjects: NEOPLASIAS RETAIS (CIRURGIA;QUIMIOTERAPIA), PROCEDIMENTOS CIRÚRGICOS OPERATÓRIOS, TERAPIA COMBINADA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SABBAGA, Jorge e BRAGHIROLI, Maria Ignez e HOFF, Paulo M. Is surgery always necessary in rectal cancer?. Oncology, v. 28, n. 7, p. 607-611, 2014Tradução . . Disponível em: http://www.cancernetwork.com/oncology-journal/surgery-always-necessary-rectal-cancer. Acesso em: 18 nov. 2024.
APA
Sabbaga, J., Braghiroli, M. I., & Hoff, P. M. (2014). Is surgery always necessary in rectal cancer? Oncology, 28( 7), 607-611. Recuperado de http://www.cancernetwork.com/oncology-journal/surgery-always-necessary-rectal-cancer
NLM
Sabbaga J, Braghiroli MI, Hoff PM. Is surgery always necessary in rectal cancer? [Internet]. Oncology. 2014 ; 28( 7): 607-611.[citado 2024 nov. 18 ] Available from: http://www.cancernetwork.com/oncology-journal/surgery-always-necessary-rectal-cancer
Vancouver
Sabbaga J, Braghiroli MI, Hoff PM. Is surgery always necessary in rectal cancer? [Internet]. Oncology. 2014 ; 28( 7): 607-611.[citado 2024 nov. 18 ] Available from: http://www.cancernetwork.com/oncology-journal/surgery-always-necessary-rectal-cancer
Artigo de periodico
Primary prevention of colorectal cancer: Myth or reality? (2014)
Teixeira, Marcela Crosara; Braghiroli, Maria Ignez; Sabbaga, Jorge; Hoff, Paulo M.
Source: World Journal of Gastroenterology. Unidade: FM
Subjects: NUTRIÇÃO, NEOPLASIAS COLORRETAIS, ATIVIDADE FÍSICA, PREVENÇÃO PRIMÁRIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TEIXEIRA, Marcela Crosara et al. Primary prevention of colorectal cancer: Myth or reality?. World Journal of Gastroenterology, v. 20, n. 41, p. 15060-15069, 2014Tradução . . Disponível em: https://doi.org/10.3748/wjg.v20.i41.15060. Acesso em: 18 nov. 2024.
APA
Teixeira, M. C., Braghiroli, M. I., Sabbaga, J., & Hoff, P. M. (2014). Primary prevention of colorectal cancer: Myth or reality? World Journal of Gastroenterology, 20( 41), 15060-15069. doi:10.3748/wjg.v20.i41.15060
NLM
Teixeira MC, Braghiroli MI, Sabbaga J, Hoff PM. Primary prevention of colorectal cancer: Myth or reality? [Internet]. World Journal of Gastroenterology. 2014 ; 20( 41): 15060-15069.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3748/wjg.v20.i41.15060
Vancouver
Teixeira MC, Braghiroli MI, Sabbaga J, Hoff PM. Primary prevention of colorectal cancer: Myth or reality? [Internet]. World Journal of Gastroenterology. 2014 ; 20( 41): 15060-15069.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3748/wjg.v20.i41.15060
Artigo de periodico
Management of colon cancer and liver metastases: Is there a role for molecularly targeted agents? (2014)
Testa, Laura; Braghirolli, Maria Ignes; Herman, Paulo; Hoff, Paulo M.
Source: Current Colorectal Cancer Reports. Unidade: FM
Subjects: NEOPLASIAS DO COLON (FISIOPATOLOGIA), NEOPLASIAS HEPÁTICAS, METÁSTASE NEOPLÁSICA, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TESTA, Laura et al. Management of colon cancer and liver metastases: Is there a role for molecularly targeted agents?. Current Colorectal Cancer Reports, v. 10, p. 133-139, 2014Tradução . . Disponível em: http://link.springer.com/article/10.1007%2Fs11888-014-0213-x. Acesso em: 18 nov. 2024.
APA
Testa, L., Braghirolli, M. I., Herman, P., & Hoff, P. M. (2014). Management of colon cancer and liver metastases: Is there a role for molecularly targeted agents? Current Colorectal Cancer Reports, 10, 133-139. Recuperado de http://link.springer.com/article/10.1007%2Fs11888-014-0213-x
NLM
Testa L, Braghirolli MI, Herman P, Hoff PM. Management of colon cancer and liver metastases: Is there a role for molecularly targeted agents? [Internet]. Current Colorectal Cancer Reports. 2014 ; 10 133-139.[citado 2024 nov. 18 ] Available from: http://link.springer.com/article/10.1007%2Fs11888-014-0213-x
Vancouver
Testa L, Braghirolli MI, Herman P, Hoff PM. Management of colon cancer and liver metastases: Is there a role for molecularly targeted agents? [Internet]. Current Colorectal Cancer Reports. 2014 ; 10 133-139.[citado 2024 nov. 18 ] Available from: http://link.springer.com/article/10.1007%2Fs11888-014-0213-x
Trabalho de evento-resumo periodico
Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil (2013)
Caires-Lima, Rafael; Protasio, Bruno M.; Takahashi, Tiago K.; Mak, Milena P.; Nakazato, Denyei; Mesquita, Cristiane S.; Takagaki, Teresa Y.; Soares, Iberê C.; Mello, Evandro S.; Hoff, Paulo M.; Alves, Venâncio A.; Castro Jr., Gilberto
Source: Journal of thoracic oncology. Conference titles: World Conference on Lung Cancer. Unidade: FM
Subjects: NEOPLASIAS PULMONARES, POLIMORFISMO, ADENOCARCINOMA, MUTAÇÃO, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAIRES-LIMA, Rafael et al. Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 18 nov. 2024. , 2013
APA
Caires-Lima, R., Protasio, B. M., Takahashi, T. K., Mak, M. P., Nakazato, D., Mesquita, C. S., et al. (2013). Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. Faculdade de Medicina, Universidade de São Paulo.
NLM
Caires-Lima R, Protasio BM, Takahashi TK, Mak MP, Nakazato D, Mesquita CS, Takagaki TY, Soares IC, Mello ES, Hoff PM, Alves VA, Castro Jr. G. Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. 2013 ; 8 S892.[citado 2024 nov. 18 ]
Vancouver
Caires-Lima R, Protasio BM, Takahashi TK, Mak MP, Nakazato D, Mesquita CS, Takagaki TY, Soares IC, Mello ES, Hoff PM, Alves VA, Castro Jr. G. Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. 2013 ; 8 S892.[citado 2024 nov. 18 ]
Artigo de periodico
Percutaneous transhepatic biliary drainage in patients with advanced solid malignancies: Prognostic factors and clinical outcomes (2013)
Teixeira, Marcela Crosara; Mak, Milena Perez; Marques, Daniel Fernandes; Capareli, Fernanda; Carnevale, Francisco Cesar; Moreira, Airton Mota; Ribeiro Jr., Ulysses; Cecconello, Ivan; Hoff, Paulo M.
Source: Journal of Gastrointestinal Cancer. Unidade: FM
Subjects: NEOPLASIAS HEPÁTICAS, DOENÇAS BILIARES, METÁSTASE NEOPLÁSICA, ICTERÍCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TEIXEIRA, Marcela Crosara et al. Percutaneous transhepatic biliary drainage in patients with advanced solid malignancies: Prognostic factors and clinical outcomes. Journal of Gastrointestinal Cancer, v. 44, n. 4, p. 398-403, 2013Tradução . . Disponível em: http://link.springer.com/article/10.1007%2Fs12029-013-9509-3. Acesso em: 18 nov. 2024.
APA
Teixeira, M. C., Mak, M. P., Marques, D. F., Capareli, F., Carnevale, F. C., Moreira, A. M., et al. (2013). Percutaneous transhepatic biliary drainage in patients with advanced solid malignancies: Prognostic factors and clinical outcomes. Journal of Gastrointestinal Cancer, 44( 4), 398-403. doi:10.1007/s12029-013-9509-3
NLM
Teixeira MC, Mak MP, Marques DF, Capareli F, Carnevale FC, Moreira AM, Ribeiro Jr. U, Cecconello I, Hoff PM. Percutaneous transhepatic biliary drainage in patients with advanced solid malignancies: Prognostic factors and clinical outcomes [Internet]. Journal of Gastrointestinal Cancer. 2013 ; 44( 4): 398-403.[citado 2024 nov. 18 ] Available from: http://link.springer.com/article/10.1007%2Fs12029-013-9509-3
Vancouver
Teixeira MC, Mak MP, Marques DF, Capareli F, Carnevale FC, Moreira AM, Ribeiro Jr. U, Cecconello I, Hoff PM. Percutaneous transhepatic biliary drainage in patients with advanced solid malignancies: Prognostic factors and clinical outcomes [Internet]. Journal of Gastrointestinal Cancer. 2013 ; 44( 4): 398-403.[citado 2024 nov. 18 ] Available from: http://link.springer.com/article/10.1007%2Fs12029-013-9509-3

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Date published

Subjects

Source title

Countries/Territories

Funding Agencies

Indexado em